We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

Expanded access is currently available for this treatment.
Verified August 2012 by Meir Medical Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT01267461
First Posted: December 28, 2010
Last Update Posted: August 10, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Tel Aviv University
Information provided by (Responsible Party):
Meir Medical Center
  Purpose
Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.

Condition Intervention
Endometrial Cancer Colon Cancer Other: Tissue sample from tumor

Study Type: Expanded Access     What is Expanded Access?

Further study details as provided by Meir Medical Center:

Intervention Details:
    Other: Tissue sample from tumor
    Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Patients with Endometrial and Colon Cancer

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01267461


Contacts
Contact: Ilan Bruchim, MD 972-9-7472561 ilan.bruchim@clalit.org.il

Sponsors and Collaborators
Meir Medical Center
Tel Aviv University
  More Information

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01267461     History of Changes
Other Study ID Numbers: 0015-10-MMC
First Submitted: December 27, 2010
First Posted: December 28, 2010
Last Update Posted: August 10, 2012
Last Verified: August 2012

Keywords provided by Meir Medical Center:
To asses the biological actions of insulin analogs in primary tumor cells

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female